TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02693561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercises
Description: Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercises
Description: Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Book
Description: Reading the self-help book.
Study: NCT03784547

Intervention type: DRUG
Intervention: Ocrelizumab
Description: already described
Study: NCT01875783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT imaging
Description: Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
Study: NCT01227486

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
Study: NCT01916876

Intervention type: OTHER
Group type: OTHER
Intervention: Integrated medical follow-up package
Description: At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice
Study: NCT04319575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: root canal treatment and intracanal medicament
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment and intracanal medicament
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.
Study: NCT03045861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
Study: NCT02210065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Description: CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
Study: NCT04006132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of Ponto 3 SuperPower
Description: Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
Study: NCT02906748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection with a syringe in new-site for parathyroid autografting
Description: new-site for parathyroid autografting, close to the antecubital vein
Study: NCT02349048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg
Description: Simeprevir 150 mg capsule orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg
Description: Simeprevir 150 mg capsule orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir 60 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir 60 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg
Description: Sofosbuvir 400 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg
Description: Sofosbuvir 400 mg tablet orally once daily.
Study: NCT03126942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novaloc
Description: Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novaloc
Description: Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator
Description: Traditional cylindrical attachment (Locator system) with pink (medium) retentive components

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator
Description: Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
Study: NCT02203825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-CS1 T-cell infusion
Description: Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
Study: NCT05726799

Intervention type: PROCEDURE
Intervention: Cryo myectomy
Description: Extended septal myecotmy using cryo energy

Intervention type: PROCEDURE
Intervention: Myectomy
Description: Classic surgical myectomy
Study: NCT00806936

Intervention type: DRUG
Intervention: human insulin
Description: Any kind of human insulin administered at the discretion of the physician

Intervention type: DRUG
Intervention: insulin analogue
Description: Any kind of insulin analogue administered at the discretion of the physician
Study: NCT01322464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 2 sprays Sativex daily in fasted state Days 4-13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: 8 sprays Sativex daily in fasted state Days 4-13.
Study: NCT04697459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronic phase
Description: 1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acute phase
Description: 30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
Study: NCT05288400

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg
Description: 1 capsule/day Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc 5mg tablet
Description: Norvasc (amlodipine) 5mg, 1 tablet/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concor 5mg tablet
Description: Concor (bisoprolol fumarate) 5mg, 1 tablet/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coversyl 5mg tablet
Description: Coversyl (perindopril arginine) 5mg, 1 tablet/day
Study: NCT03966742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis
Description: Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe.
Study: NCT00003625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02835001

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: Two sequences of 30 minutes are necessary by patient

Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Volume Reduction Coil (HEAT-LVRC)
Description: Bronchoscopy with Heat-LVRC
Study: NCT04164836

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rhinoscope
Description: more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
Study: NCT03568474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Indirect pulp capping material

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Indirect pulp capping material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer
Description: Indirect pulp capping material
Study: NCT03101228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced sitting
Description: Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
Study: NCT00597480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH (Norditropine SimpleXx®)
Description: the recommended dose in the EU of rhGH (Norditropine SimpleXx®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH norditropine simple Xx
Description: the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)
Study: NCT03451786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL
Description: Intraocular lens
Study: NCT04152577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-combination chemotherapy
Description: R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-combination chemotherapy
Description: R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Study: NCT02159729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (1 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT02906748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection with a syringe in traditional site for parathyroid autografting
Description: traditional-site for parathyroid autografting,not intensively close to the antecubital vein
Study: NCT01046708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Description: 600mg in 3 separate doses per day
Study: NCT03548948

Intervention type: OTHER
Group type: OTHER
Intervention: High heme iron diet
Description: A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.

Intervention type: OTHER
Group type: OTHER
Intervention: Low iron diet
Description: A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet.
Study: NCT02159729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 (4 mg/cm^2)
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT01794572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem cell
Description: Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication.
Study: NCT04777487

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF obtaining
Description: 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF obtaining
Description: 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF obtaining
Description: 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
Study: NCT00530114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 223
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
Study: NCT05288738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 mcg/ml
Description: 34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 2 mcg/ml
Description: 34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
Study: NCT01920880

Intervention type: OTHER
Intervention: Quantitative Sensory Testing analysis

Intervention type: OTHER
Intervention: Quantitative Sensory Testing analysis
Study: NCT00643266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recollection Training
Description: Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
Study: NCT02448030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electric stimulation
Description: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isometric exercise
Description: For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
Study: NCT03695575

Intervention type: DEVICE
Group type: OTHER
Intervention: Bone-conduction headset
Description: A bone-conduction headset paired with a microphone will be used.
Study: NCT03744351

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Samples
Description: Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal
Study: NCT04565964

Intervention type: OTHER
Group type: OTHER
Intervention: change the health behaviors to clean indoor environment
Description: Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
Study: NCT00393887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodesign IHM
Description: Biodesign IHM is placed to reinforce the hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene mesh
Description: Polypropylene mesh is used to reinforce the hernia repair.